Endonovo Therapeutics Free Cash Flow (FCF) History (ENDV)

Endonovo Therapeutics reported −$2.5M in free cash flow for fiscal 2019, an increase of $344,202 from the previous fiscal year, with a free cash flow margin of −820.08%.

View full Endonovo Therapeutics company overview

Endonovo Therapeutics free cash flow by year

Endonovo Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20192019-12-31−$2.5M$344,202—−820.08%
20182018-12-31−$2.9M$3.1M—−3468.29%
20172017-12-31−$6.0M———
20152015-12-31−$1.0M−$113,867—−23989.75%
20142014-12-31−$909,296——−3758.66%

Endonovo Therapeutics free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$909,296 to −$2.5M, a net decrease of $1.6M. Endonovo Therapeutics's latest reported quarter, Q3 2019, generated −$1.0M in free cash flow, a decrease of $187,115 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Endonovo Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about ENDV yet. Start the conversation.

Write the first post